- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05050461
Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma (LYMPHO-CoVac)
The specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and CD4 T lymphocytes (Dan JM et al., Science 2021).
Mortality from infection varies greatly depending on the age of the affected subjects and their comorbidities including a history of cancer (Liang W et al, 2020). Among these cancers, a history of malignant hemopathy in the 5 years preceding the onset of Covid-19 increases the risk of death by a factor of 3 (OpenSAFELY collaborative 2020). Among them, lymphoid hemopathies induce hypogammaglobulinemia and / or lymphopenia. These factors combined with chemotherapy and immunotherapy treatments promote the development of infections in affected individuals. Among these, are the anti-CD20 monoclonal antibodies, widely prescribed for treating B-cell non-Hodgkin lymphomas (B-NHL). They induce a deep and lasting B-cell lymphopenia, which can promote infections (Maschmeyer G et al, 2019). They reduce the production of antibodies and the constitution of memory responses to a new pathogen or to a vaccination. In addition, B lymphocytes likely have a key immunomodulatory role in the control of viral infections.
We conducted a retrospective study in 89 patients with lymphoma and Covid-19 after the first phase of the epidemic in different centers in the Île-de-France and eastern France regions (Lamure S et al. , 2020). With a 6-month follow-up, we showed a pejorative prognostic impact of anti-CD20 monoclonal antibody treatment on Covid-19-related mortality (Duléry et al, 2021).
Vaccination of these at-risk patients is therefore essential. A growing concern is how patients with B-NHL who have been vaccinated with a SARS-CoV-2 mRNA vaccine are protected against infection, depending on whether or not they have received anti-CD20 monoclonal drugs and / or chemotherapy.
Knowing the medium-term immunological evolution after vaccination against SARS-CoV-2 in patients with B-cell NHL is necessary in order to be able to adapt the therapeutic and vaccine recommendations.
The main objective of this study is to determine how recent treatment (in the year before vaccination) with anti-CD20 monoclonal antibody modifies the immune response after vaccination against SARS-CoV-2 in adults with B-NHL compared to patients who have not recently been exposed to this immunotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adult aged at least 18 years old
- Having received (at least) two injections of anti-SARS-CoV-2 messenger RNA vaccine (Pfizer and / or Moderna)
- Affiliated to social security
- consenting to the study
- Concenring cases only: Be or have been affected by B-NHL in remission, active surveillance or during first-line or second-line treatment, regardless of this treatment
Exclusion Criteria:
Patient less than 18 years old
- Patient with protective measure (curatorship, guardianship, safeguard of justice, deprived of liberty, in an emergency situation)
- Patient unable to express their consent
- Pregnant or breastfeeding woman
- Patient refusing to participate
- Concenring cases: Patient whose life expectancy related to B-NHL is less than 6 months, History of allogeneic hematopoietic stem cell transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cases
Patients with a history of B-NHL
|
Immunological analyses will be performed at inclusion in both arms
|
Other: Controls
Spouses of cases
|
Immunological analyses will be performed at inclusion in both arms
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison of humoral (especially anti-SARS-CoV-2 antibody levels) and T cell memory responses in adult patients with B-NHL depending on whether or not they were exposed to anti-CD20 monoclonal antibody treatment in the year before vaccination.
Time Frame: at inclusion
|
at inclusion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P21/08 - LYMPHO-CoVac
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaccination Failure
-
Centre Hospitalier Universitaire de NiceCompletedVaccination Failure
-
University of Roma La SapienzaCompletedVaccination Failure | Vaccination Adverse Events | Specific Antibody ResponseItaly
-
Lifespan Healthcare Resource LimitedBill and Melinda Gates FoundationUnknown
-
Aga Khan UniversityWorld Health OrganizationUnknownVaccination FailurePakistan
-
Aga Khan UniversityWorld Health OrganizationUnknown
-
University of AlbertaMerck Canada Inc.Not yet recruitingVaccine Response Impaired | Vaccination Failure
-
University of PennsylvaniaCompletedVaccine Refusal | Vaccination Hesitancy | Human Papillomavirus VaccinationUnited States
-
National Cancer Institute (NCI)CompletedHPV16 Anitbody Levels Post Vaccination | HPV18 Antibody Levels Post VaccinationUganda
-
Indiana UniversityNational Center for Advancing Translational Sciences (NCATS)Recruiting
-
Columbia UniversitySeattle Children's Hospital; New York Presbyterian Hospital; Agency for Healthcare...Completed
Clinical Trials on Immunological analyses
-
Centre Leon BerardUnknown
-
Hospices Civils de LyonUnknown
-
Mario Negri Institute for Pharmacological ResearchTerminated
-
IRCCS SYNLAB SDNFondazione Santobono PausiliponRecruitingAcute Lymphoblastic Leukemia, PediatricItaly
-
Centre Hospitalier Universitaire de la RéunionRecruiting
-
IRCCS Burlo GarofoloRecruitingNephrotic SyndromeItaly
-
Royal Marsden NHS Foundation TrustRecruiting
-
Mario Negri Institute for Pharmacological ResearchTerminated
-
Hospices Civils de LyonCompleted
-
Hôpital le VinatierCompleted